Literature DB >> 8669925

Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

R Korinthenberg1, J S Mönting.   

Abstract

A retrospective multicentre study was performed to investigate the natural history and treatment effects in childhood Guillain-Barré syndrome in a large number of patients. Structured questionnaires were sent to 155 paediatric hospitals for details of patients who conformed to internationally accepted diagnostic criteria and who were treated from spring 1989 to summer 1994. Sixty nine hospitals reported data of 175 patients aged 11 months to 17.7 years. At the height of the disease 26% of the patients remained able to walk, but 16% had to be artificially ventilated. The median time from onset of symptoms to first recovery was 17 days, to walk unaided 37 days, and to be free of symptoms 66 days. There was a large group with a benign and a smaller one with a more protracted course. At long term follow up, 98/106 patients were free of symptoms and the remainder were able to walk unaided. Maximum disability grade was the most powerful prognostic factor. In children unable to walk but not yet tetraplegic, immunoglobulins were able to accelerate recovery. Corticosteroids were less potent. Plasmapheresis could not be evaluated because it was administered only in the most severe cases. The natural history of Guillain-Barré syndrome in children is extremely variable and more benign than in adults. Treatment with immunoglobulins should be considered in patients unable to walk. Corticosteroids are not as effective and should be withheld except when, in protracted courses, suspicion of chronic inflammatory demyelinating polyneuropathy arises.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669925      PMCID: PMC1511471          DOI: 10.1136/adc.74.4.281

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  44 in total

1.  Aseptic meningitis associated with high dose intravenous immunoglobulin therapy.

Authors:  J D Watson; J Gibson; D E Joshua; H Kronenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

Review 2.  The Guillain-Barré syndrome.

Authors:  A H Ropper
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

3.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

4.  Age-associated changes in the symptomatology of Guillain-Barré syndrome in children.

Authors:  Y Sakakihara; S Kamoshita
Journal:  Dev Med Child Neurol       Date:  1991-07       Impact factor: 5.449

5.  Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome.

Authors:  E Shahar; E G Murphy; C M Roifman
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

6.  Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome.

Authors:  H Rantala; M Uhari; M Niemelä
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

7.  Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis.

Authors:  D Y Bradshaw; H R Jones
Journal:  Muscle Nerve       Date:  1992-04       Impact factor: 3.217

8.  Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.

Authors:  R P Kleyweg; F G van der Meché
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

9.  The role of plasmapheresis in childhood Guillain-Barré syndrome.

Authors:  M A Epstein; J T Sladky
Journal:  Ann Neurol       Date:  1990-07       Impact factor: 10.422

10.  Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood.

Authors:  A A al-Qudah
Journal:  J Child Neurol       Date:  1994-04       Impact factor: 1.987

View more
  22 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

3.  Exchange transfusion as an alternative therapy for recurrent severe Guillain-Barre syndrome.

Authors:  Arun K Baranwal; Veena R Parmar
Journal:  Indian J Pediatr       Date:  2007-07       Impact factor: 1.967

4.  Intravenous immunoglobulins in severe Guillian-Barre syndrome in childhood.

Authors:  Preeti Shanbag; Cynthia Amirtharaj; Ashish Pathak
Journal:  Indian J Pediatr       Date:  2003-07       Impact factor: 1.967

5.  Intravenous IgG in Guillain-Barré syndrome.

Authors:  R A Hughes
Journal:  BMJ       Date:  1996-08-17

6.  Guillain-Barré syndrome in children: subtypes and outcome.

Authors:  Zeynep Selen Karalok; Birce Dilge Taskin; Zeliha Brohi Yanginlar; Esra Gurkas; Alev Guven; Aydan Degerliyurt; Ece Unlu; Gulsen Kose
Journal:  Childs Nerv Syst       Date:  2018-06-14       Impact factor: 1.475

7.  How Different is AMAN from AIDP in Childhood GBS? A Prospective Study from North India.

Authors:  Pradeep Kumar Gupta; Pratibha Singhi; Sunit Singhi; Ananthanarayanan Kasinathan; Naveen Sankhyan
Journal:  Indian J Pediatr       Date:  2019-01-12       Impact factor: 1.967

Review 8.  Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review.

Authors:  Kate O Poropatich; Christa L Fischer Walker; Robert E Black
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

9.  Prospective study of children with Guillain-Barre syndrome.

Authors:  Roshan Lal Koul; Amna Alfutaisi
Journal:  Indian J Pediatr       Date:  2008-06-25       Impact factor: 1.967

10.  Outcome in childhood Guillain-Barré syndrome.

Authors:  Veena Kalra; Naveen Sankhyan; Suvasini Sharma; Sheffali Gulati; Rama Choudhry; Benu Dhawan
Journal:  Indian J Pediatr       Date:  2009-04-16       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.